Top News

New Antibiotic Puts up a Fight Against Superbugs

January 09, 2015

NovoBiotic’s first-in-class antibiotic, teixobactin, proves strong in the battle to kill drug-resistant bacteria.

FDA Extends Enforcement Deadline for Track and Trace

January 09, 2015

A guidance document published just before the Jan. 1, 2015 deadline adds a four-month grace period.

CVS Health Announces Hepatitis C Drug Exclusivity Deal with Gilead

January 06, 2015

The exclusivity deal mirrors that of the recent deal between Express Scripts and AbbVie for Viekira Pak.

Janssen to Pay Up to $835 Million for Antisense Therapy

January 05, 2015

Isis Pharmaceuticals announced that it entered into an agreement with Janssen Biotech to discover and develop antisense drugs for autoimmune disorders of the GI tract.

FDA Approves First Ebola Test for Emergency Use

December 29, 2014

Roche’s LightMix Ebola test can give results in around three hours.

FDA Approves Genentech’s Combination Leukemia Treatment

December 29, 2014

When used in combination with chlorambucil to treat chronic lymphocytic leukemia, Gazyva was found to be more effective than Rituxan.

Ignyta’s Neuroblastoma Treatment Receives Orphan Drug Designation

December 29, 2014

Entrectinib has received FDA’s orphan drug and rare pediatric disease designations for the treatment of neuroblastoma.

FDA Approves Opdivo for the Treatment of Melanoma

December 23, 2014

Approval of anti-PD-1 antibody Opdivo represents a major milestone for patients who no longer respond to existing treatments for melanoma.

Express Scripts and AbbVie Ink Landmark Formulary Exclusivity Deal

December 22, 2014

Pharmacy benefit manager Express Scripts offers Viekira Pak at a discount and excludes the drug’s higher-priced competitors from its formulary.

EMA Recommends Approval of First Stem-Cell Therapy

December 19, 2014

The first stem-cell medication approved in the EU promotes regeneration and healing to the outer layer of the cornea.